Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms
Interventions: DRUG: Neratinib|DRUG: Fulvestrant|DRUG: Trastuzumab|PROCEDURE: Tumor biopsy|PROCEDURE: Research blood sample
Sponsor: Washington University School of Medicine
Collaborators: Puma Biotechnology, Inc.|United States Department of Defense